An essential protein for normal stem cell renewal also promotes the growth of breast cancer stem cells when it's overproduced in those cells, researchers at The University of Texas MD Anderson Cancer Center report in the February edition of Cancer Cell.
In mouse and lab experiments, the team also discovered that two drugs block the cascade of molecular events that they describe in the paper, thwarting formation of breast tumor-initiating cells.
"Overexpression of the EZH2 protein has been linked to breast cancer progression, but the molecular details of that connection were unknown," said senior author Mien-Chie Hung, Ph.D., professor and chair of MD Anderson's Department of Molecular and Cellular Oncology.
"Tumor-initiating cancer cells that arise from the primary cancer stem cells also are thought to drive cancer progression," Hung said. "This research connects EZH2 to the growth of breast tumor-initiating cells."
EZH2 blocks DNA damage repair
The molecular chain of events that improves self-renewal, survival and growth of these breast cancer stem cells can be initiated by oxygen-starved portions of a tumor, Hung said. This hypoxia stimulates a protein that in turn causes overexpression of EZH2.
Abundant EZH2, the team showed, dampens production of an important protein involved in DNA damage repair. Unrepaired chromosomal damage then amplifies production of RAF1, which unleashes a molecular cascade that promotes expansion of breast tumor-initiating cells and cancer progression.
Two drugs slash breast cancer stem cell population
The team tested five anti-cancer drugs against a culture of breast cancer cells and in tumor samples of human breast cancer in a mouse model. Sorafenib, a RAF inhibitor also known as Nexavar, eliminated more cancer stem cells and blocked tumor formation better than the other four.
Sorafenib inhibits multiple targets, so the researchers also tested an experimental drug called AZD6244, which specifically inhibits the MEK-ERK kinase cascade launched by RAF1. They found the drug eliminates EZH2-promoted breast cancer stem cells and blocks the formation of precancerous mammospheres.
"The drugs' inhibition of the breast tumor-initiating cells reveals a previously unidentified therapeutic effect for RAF1-ERK inhibitors to prevent breast cancer progression," Hung said. AZD6244 is being tested in multiple clinical trials, he noted, and it will be interesting to see whether the cancer-stem-cell-killing ability will be induced in those trials.
Hunting down a dangerous pathway
Breast cancer stem cells can be sorted from other primary cancer cells by the presence of the surface protein CD44 and low or absent CD24 in tumor cells.
The researchers found that high expression of EZH2 in breast cancer stem cells reduced the levels of the tumor suppressor RAD1 and correlated with high-grade tumors in a sample of 168 human breast cancer tumors. It also increased the number of tumor-initiating cells in culture.
EZH2 also is heavily expressed, and RAD1 diminished, by lack of oxygen in the tumor's environment, which causes activation of the HIF1a(alpha) protein. HIF1a(alpha), the researchers found, activates the EZH2 gene by binding to the gene's promoter region.
With RAD1 unable to repair damage, amplified RAF1 triggers the MEK-ERK-ß-Catenin pathway, a well-known cancer promoting molecular pathway. The team showed EZH1 enhances this signaling pathway, which they found correlates with breast cancer progression.
In December, Hung and colleagues published a paper in Nature Cell Biology showing that the enzyme CDK1 shuts down EZH2.
Research was funded by grants from the National Cancer Institute, including those for MD Anderson's Specialized Program in Research Excellence (SPORE) for breast cancer and MD Anderson's cancer center support grant; the U.S. Department of Defense, the National Science Council of Taiwan, the Cancer Center of Excellence in Taiwan, National Breast Cancer Foundation, Inc., Kadoorie Charitable Foundation, Beast Cancer Research Foundation and the MD Anderson-China Medical University and Hospital Sister Institution Fund.
Co-authors with Hun, who also is MD Anderson vice president of basic research, are lead author Chun-Ju Chang, Ph.D., Jer-Yen Yang, Ph.D., Weiya Xia, M.D., Chun-Te Chen, Xiaoming Xie, Ph.D., Chi-Hong Chao, Ph.D., and Jung-Mao Hsu, all of MD Anderson's Department of Molecular and Cellular Oncology; Wendy Woodward, M.D., Ph.D., MD Anderson's Department of Radiation Oncology; and Gabriel Hortobagyi, M.D., of MD Anderson's Department of Breast Medical Oncology. Hsu is a student in The University of Texas Graduate School of Biomedical Sciences, a joint program of MD Anderson and The University of Texas Health Science Center at Houston (UTHealth).
He also is affiliated with the Center for Molecular Medicine and the Graduate Institute of Cancer Biology, both of the China Medical University Hospital in Taichung, Taiwan and with Asia University in Taichung.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For seven of the past nine years, including 2010, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.
Scott Merville | EurekAlert!
Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View
22.06.2018 | University of Sussex
New cellular pathway helps explain how inflammation leads to artery disease
22.06.2018 | Cedars-Sinai Medical Center
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
22.06.2018 | Materials Sciences
22.06.2018 | Earth Sciences
22.06.2018 | Life Sciences